Author

Yu Li

h-index 0 View on Semantic Scholar

We have 3 of 3 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Deep learning-based CT model for non-invasive prediction of tertiary lymphoid structures in pancreatic cancer: a multicenter study with prospective validation in an immunochemotherapy cohort

Abstract Background Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies. Tertiary lymphoid structures (TLS) have emerged as key components of the tumor immune microenvironment, associated with improved survival and enhanced immunotherapy response. However, non-invasive detection of TLS r...

Hao-Peng Yu, Xiao-Ying Li, Xuan Cheng et al. · Journal for ImmunoTherapy of... · 0 citations

Review Open access Sep 2026

Bispecific antibody-drug conjugates in cancer: therapeutic-window determinants, tumour-immune interactions, and clinical translation

Antibody-drug conjugates (ADCs) have established targeted payload delivery as an important anticancer strategy, but their efficacy remains constrained by antigen heterogeneity, incomplete internalisation, resistance and dose-limiting toxicity. Bispecific antibody-drug conjugates (BsADCs) add a second antigen- or epitop...

Yang Li, Yu Li, Rong-Fong Huang et al. · Frontiers in Immunology · 0 citations

#gene editing Review Open access Sep 2026

Engineering strategies to address immune and delivery barriers in pancreatic ductal adenocarcinoma: a barrier-matched translational framework

This review evaluates oncolytic virotherapy, gene-editing technologies, engineered immune-cell therapies, nanotechnology-enabled delivery systems, and artificial intelligence-assisted precision oncology according to the PDAC barriers they are intended to address and the maturity of the supporting evidence.

Yang Li, Yu Li, Jia Fan et al. · Frontiers in Immunology · 0 citations